How to Localize Labels and Instructions for Overseas Registration of Laboratory Equipment?

Key Summary

In overseas registration of laboratory equipment, localizing labels and instructions is not simple translation but a systematic conversion that accounts for the target country's medical device regulatory scope, product classification, and registration pathway. First, the manufacturer must determine whether the device qualifies as a medical device. For example, biochemical analyzers and PCR instruments used for clinical diagnosis are generally classified as medical devices, whereas purely research-use equipment may fall outside device regulations. Next, the risk class should be assessed. Low-risk devices may be eligible for self-declaration or simplified registration, while medium- and high-risk devices require submission of full technical documentation. Label and instruction content must align with risk management, performance verification, and clinical evaluation conclusions; intended use statements must not be exaggerated. Existing NMPA, CE, FDA, ISO 13485, and MDSAP documentation can be reused as a baseline, but the target country's language, warning symbols, units of measurement, and local representative information must be localized. Common risks include ignoring local regulatory terminology, omitting contraindication clauses, failing to designate a local agent, and unclear certificate control, all of which can lead to deficiency letters or post-market corrective actions. For multi-country registration, it is recommended to establish a core documentation library with a country-specific difference matrix, appoint qualified local representatives, and continuously track label regulatory changes after market entry to ensure controlled change and renewal processes.

Applicable Scenarios and Core Issues

Overseas registration of laboratory equipment is often treated as 'instrument export.' However, once a device is used for human sample testing, auxiliary diagnosis, or clinical decision-making, it may fall within the target country's medical device regulatory scope. Common products include biochemical analyzers, hematology analyzers, PCR instruments, microplate readers, urine analyzers, pathology microtomes, and centrifuges.

The core issue is not 'translating labels and instructions' but 'determining the basis for localization.' Target country regulations on labels and instructions are directly linked to product classification, registration pathway, intended use, and environment of use. If regulatory status is not confirmed first, even the most accurate translation will not pass review.

Localization is not merely a language conversion. It is the process of converting the original country's labels, instructions, packaging marks, symbols, warnings, units of measurement, contraindications, and precautions into a version acceptable and compliant with the target market. Each market has different language, fonts, symbol systems, and standards.

Labels and instructions are also a key focus of post-market surveillance and a common reason for application rejection or deficiency requests. Companies must incorporate localization into the early stage of the registration project rather than handling it as a last-minute task before submission.

Registration Decision Logic

Step 1: Determine Product Nature

Laboratory equipment is considered a medical device only when used for medical purposes. For example, a general-purpose centrifuge for research is not a medical device, but a dedicated centrifuge for clinical sample preparation may be classified as one. Companies should consult the target country's regulations and product classification lists.

Step 2: Assess Risk Class

Under GHWP member countries, most laboratory equipment falls under medical device regulations, with risk classes ranging from A to D. Low-risk devices are typically subject to manufacturer's declaration of conformity, while medium- and high-risk devices require notified body or regulatory authority review. Different risk classes require different levels of label and instruction review.

Step 3: Determine Registration Pathway and Applicant Status

Companies may apply directly as an overseas manufacturer or submit through a local representative or authorized representative. Most countries require overseas applicants to designate a local agent responsible for communication, regulatory inquiries, and post-market reporting.

Step 4: Assess Reusability of Existing Documentation

Existing NMPA registration certificates, CE certificates, FDA 510(k) or PMA, ISO 13485 certificates, and MDSAP certificates can serve as core evidence. However, label and instruction format and content requirements vary by country; reuse does not mean direct copying.

Step 5: Confirm Localization Scope

Beyond labels and instructions, this includes user manuals, quick guides, packaging boxes, outer carton markings, warning labels, electronic labels, electronic IFU versions, and certificates of conformity. Each item must be checked against the target country's regulatory checklist.

Documentation and Evidence

The following core documents are required for label and instruction localization:

• Original labels and instructions in editable vector source files.
• Intended use and indication statements for determining applicable populations and clinical use.
• Risk management report, including risk analysis corresponding to label warnings and contraindications.
• Performance verification data and clinical evaluation documents as evidence for label performance claims.
• Product classification rationale or pre-classification documents.
• Original country registration certificates and CE/FDA certificates to demonstrate the validity of baseline documentation.
• Draft versions in the target language, reviewed by local regulatory experts before submission.
• Packaging, sterilization, storage, and transport condition validation reports for environmental warnings.

A translation consistency declaration must also be provided, confirming that the translated version matches the original and identifying the responsible party for translation. Some countries require translation company qualifications or notarization; companies should confirm this in advance.

For technical documentation, IEC 61010 series safety standards, ISO 14971 risk management, and ISO 13485 quality system documents must correspond to label content. If the device includes software, user interface screenshots and descriptions must be provided.

For countries with specific measurement systems, labels must use local legal units while retaining international units. For example, the United States uses imperial units, while some Middle Eastern countries use metric but accept bilingual Arabic and English.

Common Mistakes

Companies frequently encounter the following issues during label and instruction localization:

• Treating 'translation' as 'localization'—only converting language without adjusting format and regulatory requirements.
• Failing to confirm the target country's definition of a medical device and blindly following research instrument export procedures.
• Ignoring mandatory expressions for legal terms and warnings in the target language.
• Directly reusing CE label warning symbols when the target country requires local text warnings.
• Omitting indications, contraindications, side effects, or warning hierarchy structures in the translated instructions.
• Failing to designate a local agent, halting registration and post-market change processes.
• Selecting the wrong registration pathway, such as submitting a low-risk device as high-risk.
• Modifying original technical parameters during localization without updating the corresponding technical documentation.

These errors often lead to deficiency requests, prolonged correction cycles, or even rejection. Companies should engage experienced regulatory consultants in the target country for gap analysis before submission.

Preparation Checklist for Companies

Companies can advance label and instruction localization through the following milestones:

• Establish a cross-functional team including regulatory affairs, R&D, quality, production, and marketing.
• Collect regulations, standards, and classification lists for all target countries.
• Determine whether the product qualifies as a medical device and complete preliminary risk class judgment.
• Compile a list of existing NMPA, CE, FDA, MDSAP certificates and reports.
• Create a complete documentation matrix mapping each country's label and instruction requirements.
• Lock the original version before translation to avoid multiple versions causing errors.
• Engage professional translation or localization services with medical translation review.
• Have local representatives or consultants conduct regulatory compliance review.
• Finalize labels and instructions and retain translation consistency declarations.
• Continuously track regulatory changes after market entry and update labels and instructions accordingly.

This checklist helps companies maintain progress synchronously across multiple country registrations and reduces redundant efforts.

AIMEILI Regulatory Interpretation and Business Impact

Regulatory Interpretation

The most common misjudgment is considering labels and instructions as a 'supporting document' to registration. In reality, they are the first technical documents reviewers examine. Many projects obtain registration certificates only to face recalls or suspensions due to label non-compliance—the root cause is insufficient localization depth in the early stages.

In the early project phase, priority should be given to regulatory status determination and gap analysis. Ideally, this should start six to eight months before formal submission. Companies may commission a regulatory consulting firm to perform a target market regulatory gap analysis, identifying which elements must comply with local standards versus those that may reference ISO/IEC standards.

Reusable materials include original technical documentation, safety standards, and performance verification reports. Mandatory localizations include language, format, warning levels, units of measurement, indication statements, and local agent information. CE labels must not be directly affixed to products sold in other countries.

Business Impact

Local agents and certificate control are critical. Certificates are typically applied for with the assistance of agents, but ownership must remain with the manufacturer. Otherwise, future changes, renewals, or agent transfers may result in loss of control. Any post-market changes to labels and instructions must be assessed to determine whether a new registration or amendment is required.

For multi-country registration, building a 'core documentation library + country-specific differentiation' system is advisable. The core library maintains uniform technical data, while country-specific label differences are recorded in a differentiation matrix. This reduces duplicate effort and enables rapid issue identification during deficiency responses.

Frequently Asked Questions

If laboratory equipment is for research only and not for clinical diagnosis, is label localization still required?

If the product clearly does not fall under the target country's medical device definition, it can generally be exported as a general industrial product or laboratory equipment. In that case, label localization mainly meets end-user and technical standard requirements. However, if the instructions contain descriptions of clinical diagnosis, screening, or disease management, the product may be classified as a medical device. Companies should strictly control intended use language to avoid regulatory upgrade due to promotional claims.

Are label language requirements uniform across different countries?

No. The EU typically requires official languages of the member state, but some countries accept English; CIS countries require Russian; Saudi Arabia requires bilingual Arabic and English; China requires Chinese; Brazil requires Portuguese; Indonesia and Vietnam require local languages. Additionally, certification labels, warnings, and symbols may have different page layouts. Companies should establish a language version management process to prevent mixing up language packs.

Does every country require a separate instruction localization review for multi-country registration?

Yes, because each country has different regulations and review standards. Even with GHWP harmonization efforts, specific registrations follow national requirements. Companies should have local agents or consultants review the final version rather than relying solely on internal translation. The same core document may require only minor adjustments in different countries, but differences must be recorded and traceable.

For further information, please contact AIMEILI. This content is based on AIMEILI's regulatory practice database, medical device international registration knowledge base, and public regulatory information. Specific projects should be evaluated based on the latest requirements of the target country's regulatory authority and the product's technical documentation.